0.2157
price up icon2.23%   0.0047
after-market Handel nachbörslich: .22 0.0043 +1.99%
loading
Schlusskurs vom Vortag:
$0.211
Offen:
$0.2168
24-Stunden-Volumen:
1.05M
Relative Volume:
0.17
Marktkapitalisierung:
$3.86M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-17.41M
KGV:
-0.0656
EPS:
-3.29
Netto-Cashflow:
$-11.73M
1W Leistung:
-25.10%
1M Leistung:
+8.66%
6M Leistung:
-73.04%
1J Leistung:
-97.42%
1-Tages-Spanne:
Value
$0.2022
$0.2214
1-Wochen-Bereich:
Value
$0.2022
$0.285
52-Wochen-Spanne:
Value
$0.138
$10.80

Aptevo Therapeutics Inc Stock (APVO) Company Profile

Name
Firmenname
Aptevo Therapeutics Inc
Name
Telefon
206-838-0500
Name
Adresse
2401 4TH AVE., SEATTLE, WA
Name
Mitarbeiter
40
Name
Twitter
@aptevo
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
APVO's Discussions on Twitter

Vergleichen Sie APVO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
APVO 0.2157 3.86M 12.99M -17.41M -11.73M -3.29
VRTX 467.01 119.87B 10.63B -479.80M -1.35B 13.33
REGN 762.00 83.27B 13.85B 4.65B 3.32B 35.06
ARGX 567.90 33.96B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.18B 2.09B -332.26M 16.06M -4.14
BNTX 101.87 24.42B 3.30B -501.07M 1.03B 11.54

Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2018-11-05 Eingeleitet Ladenburg Thalmann Buy
2017-10-05 Fortgesetzt Piper Jaffray Overweight

Aptevo Therapeutics Inc Aktie (APVO) Neueste Nachrichten

pulisher
Nov 17, 2024

Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated at StockNews.com - Defense World

Nov 17, 2024
pulisher
Nov 14, 2024

Armistice Capital, LLC's Strategic Acquisition of Aptevo Therape - GuruFocus.com

Nov 14, 2024
pulisher
Nov 11, 2024

Alligator Bioscience reports positive results for APV-527 in Phase 1 study - Marketscreener.com

Nov 11, 2024
pulisher
Nov 11, 2024

Alligator Bioscience announces positive results for APV-527 - Marketscreener.com

Nov 11, 2024
pulisher
Nov 11, 2024

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial - AccessWire

Nov 11, 2024
pulisher
Nov 11, 2024

Aptevo's Cancer Drug Shows Promise: 56% of Patients Achieve Disease Stability in Phase 1 | APVO Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 08, 2024

Hudson Bay Capital Management LP's Strategic Acquisition in Aptevo Therapeutics Inc - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Aptevo Therapeutics Inc (APVO) Quarterly 10-Q Report - Quartz

Nov 08, 2024
pulisher
Nov 07, 2024

Aptevo Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update - AccessWire

Nov 07, 2024
pulisher
Nov 07, 2024

Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews.com - Defense World

Nov 07, 2024
pulisher
Nov 06, 2024

Alligator Bioscience to present positive data for mitazalimab at SITC - Marketscreener.com

Nov 06, 2024
pulisher
Oct 31, 2024

Aptevo Therapeutics Inc (NASDAQ: APVO) Has Great Upside Potential - Stocks Register

Oct 31, 2024
pulisher
Oct 30, 2024

Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World

Oct 30, 2024
pulisher
Oct 29, 2024

Alligator Bioscience presents positive interim data from Phase 1 study - Marketscreener.com

Oct 29, 2024
pulisher
Oct 29, 2024

Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024 - AccessWire

Oct 29, 2024
pulisher
Oct 29, 2024

Aptevo and Alligator Bioscience to present Phase 1 trial data at SITC - Investing.com UK

Oct 29, 2024
pulisher
Oct 26, 2024

Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update - Defense World

Oct 26, 2024
pulisher
Oct 26, 2024

Aptevo Therapeutics secures shareholder nod for key proposals By Investing.com - Investing.com South Africa

Oct 26, 2024
pulisher
Oct 25, 2024

Aptevo Therapeutics secures shareholder nod for key proposals - Investing.com India

Oct 25, 2024
pulisher
Oct 21, 2024

Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket - Benzinga

Oct 21, 2024
pulisher
Oct 15, 2024

There is no doubt that Aptevo Therapeutics Inc (APVO) ticks all the boxes. - SETE News

Oct 15, 2024
pulisher
Oct 14, 2024

Aptevo Therapeutics Inc (NASDAQ: APVO) – An Analysis Is What You Need - Stocks Register

Oct 14, 2024
pulisher
Oct 14, 2024

Stock Market Recap: Aptevo Therapeutics Inc (APVO) Concludes at 0.15, a -2.87 Surge/Decline - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

A stock that deserves closer examination: Aptevo Therapeutics Inc (APVO) - US Post News

Oct 14, 2024
pulisher
Oct 12, 2024

APVO stock plunges to 52-week low of $0.14 amid market challenges - Investing.com Australia

Oct 12, 2024
pulisher
Oct 12, 2024

APVO stock plunges to 52-week low of $0.14 amid market challenges By Investing.com - Investing.com South Africa

Oct 12, 2024
pulisher
Oct 11, 2024

You might want to take a look at Aptevo Therapeutics Inc (APVO) now - SETE News

Oct 11, 2024
pulisher
Oct 09, 2024

APVO’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Oct 09, 2024
pulisher
Oct 08, 2024

Gaining Ground: Aptevo Therapeutics Inc (APVO) Closes Lower at 0.16, Down -2.60 - The Dwinnex

Oct 08, 2024
pulisher
Oct 08, 2024

Aptevo Therapeutics Inc (APVO) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News

Oct 08, 2024
pulisher
Oct 06, 2024

Aptevo Therapeutics (NASDAQ:APVO) Research Coverage Started at StockNews.com - Defense World

Oct 06, 2024
pulisher
Oct 06, 2024

Research Analysts’ Updated EPS Estimates for October 6th (APVO, CNP, FDX, FLNT, FRD, GALT, HOPE, KBR, LSXMK, NVGS) - Defense World

Oct 06, 2024
pulisher
Oct 03, 2024

Aptevo Therapeutics Inc (APVO)’s stock decline to 0.16 per share - US Post News

Oct 03, 2024
pulisher
Oct 03, 2024

APVO Stock Update: Aptevo Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle

Oct 03, 2024
pulisher
Oct 02, 2024

Financial Metrics Check: Aptevo Therapeutics Inc (APVO)’s Ratios for Trailing Twelve Months - The Dwinnex

Oct 02, 2024
pulisher
Sep 29, 2024

Certain Restricted Stock Units of Aptevo Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2024. - Marketscreener.com

Sep 29, 2024
pulisher
Sep 27, 2024

Aptevo Therapeutics (NASDAQ:APVO) Stock Quotes, Forecast and News Summary - Benzinga

Sep 27, 2024
pulisher
Sep 27, 2024

Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.com - Defense World

Sep 27, 2024
pulisher
Sep 26, 2024

Aptevo Therapeutics Inc Inc. (APVO) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Sep 26, 2024
pulisher
Sep 25, 2024

Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Down 78.8% in September - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Short Interest in Advantest Co. (OTCMKTS:ATEYY) Declines By 85.7% - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

Applied Therapeutics (NASDAQ:APLT) Stock Price Up 5.2% - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Astria Therapeutics (NASDAQ:ATXS) Shares Gap Down to $12.50 - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

DRW Securities LLC Invests $117,000 in Patterson-UTI Energy, Inc. (NASDAQ:PTEN) - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Gabelli Funds LLC Raises Stake in Aptiv PLC (NYSE:APTV) - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Aptevo Therapeutics Inc. (NASDAQ:APVO) to Post Q3 2024 Earnings of ($0.57) Per Share, Roth Capital Forecasts - Defense World

Sep 25, 2024
pulisher
Sep 24, 2024

Aptiv PLC stock rises Tuesday, outperforms market - MarketWatch

Sep 24, 2024
pulisher
Sep 24, 2024

Logos Global Management LP Sells 750,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Patterson-UTI Energy (NASDAQ:PTEN) Shares Down 3.5% - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

PTEN’s Q2 earnings estimates: What investors need to know - US Post News

Sep 24, 2024

Finanzdaten der Aptevo Therapeutics Inc-Aktie (APVO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 3.66%
$76.97
price up icon 1.45%
$39.51
price up icon 7.22%
$359.21
price down icon 1.11%
$187.69
price down icon 0.81%
$101.87
price up icon 2.16%
Kapitalisierung:     |  Volumen (24h):